Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Overview of attention for article published in Annals of Oncology, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 3 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 3 X users

patent: 1 patent
wikipedia: 1 Wikipedia page
reddit: 1 Redditor

Readers on

mendeley: 202 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,752 followers.

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I https://t.co/T2ux1Iv5BM #hvhebron #onco [Text complet] @Annals_Oncology

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I https://t.co/Hjcs45Adlw

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian #cancer: primary analysis of FORWARD I https://t.co/kLHbaY2dOl #OvarianCancer

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.